Metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum

Medicinal Benefits:

Crognoc 400 Injection contains Bevacizumab, a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Crognoc 400 Injection works against a protein called vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) inhibition limits the flow of oxygen and nutrients to the tumour cells, causing them to shrink or cease developing. Thus, it helps treat cancer.

Crognoc 400 Injection Substitute

Advamab 400 Injection 16 ml

Adcimab 400 mg Injection 16 ml

Avastimab 400mg Injection

Bevarest-400 Injection 16 ml

Bevazza 400 mg/16 ml Injection 16 ml

Bevicra 400 mg Injection 16 ml

Bevakalp 400 mg Injection 16 ml

Bevaro 400 Injection 16 ml

Bevnexxa 400mg Injection

Bryxta 400 Injection 16 ml

Halsbev 400 Injection 16 ml

Krabeva 400 mg Injection 16 ml

Ivzumab 400 mg Injection 16 ml

Verified Ingredients and Effects

FAQs